دورية أكاديمية
Immunosuppression regimen and latitude impact keratinocyte carcinoma risk in U.S. liver transplant recipients.
| العنوان: | Immunosuppression regimen and latitude impact keratinocyte carcinoma risk in U.S. liver transplant recipients. |
|---|---|
| المؤلفون: | Rosenthal BE; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Schaubel DE; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA., Lewis JD; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.; Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Margolis DJ; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Goldberg DS; Division of Digestive Health and Liver Diseases, Department of Medicine, Miller School of Medicine at the University of Miami, Miami, FL, USA., Bittermann T; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA. Therese.Bittermann@pennmedicine.upenn.edu.; Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Therese.Bittermann@pennmedicine.upenn.edu.; Hospital of the University of Pennsylvania, 2 Dulles - Penn Transplant Institute, 3400 Spruce Street, Philadelphia, PA, 19104, USA. Therese.Bittermann@pennmedicine.upenn.edu. |
| المصدر: | Archives of dermatological research [Arch Dermatol Res] 2024 Sep 26; Vol. 316 (9), pp. 641. Date of Electronic Publication: 2024 Sep 26. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8000462 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-069X (Electronic) Linking ISSN: 03403696 NLM ISO Abbreviation: Arch Dermatol Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer Verlag |
| مواضيع طبية MeSH: | Liver Transplantation*/adverse effects , Liver Transplantation*/statistics & numerical data , Immunosuppressive Agents*/adverse effects , Skin Neoplasms*/epidemiology , Immunosuppression Therapy*/adverse effects, Humans ; Middle Aged ; Male ; Female ; Retrospective Studies ; Aged ; United States/epidemiology ; Risk Factors ; Incidence ; Keratinocytes/immunology ; Calcineurin Inhibitors/adverse effects ; Carcinoma, Basal Cell/epidemiology |
| مستخلص: | Immunosuppression after solid organ transplantation is associated with an increased risk of keratinocyte carcinoma (KC). Despite its established morbidity, KC risk in liver transplant (LT) recipients is understudied, including the contribution of immunosuppression regimen and latitude. A retrospective cohort of 9,966 adult first LT alone recipients alive with their native allograft at 1-year post-LT without prior KC between 2007 and 2016 were identified using linked data from the Organ Procurement and Transplantation Network and Medicare administrative claims. The primary exposures were immunosuppression regimen and latitude of residence. The primary outcome was incident, de novo KC occurring at least 1-year after LT. Adjusted Cox regression analysis stratified by transplant center was used in all analyses. The cohort was 63.4% male, 70.2% White and with median age 61 years (interquartile range, IQR, 54-66) at transplant. Calcineurin inhibitor (CNI) with anti-metabolite combination was independently associated with incident KC when measured as intention-to-treat (adjusted hazard ratio (aHR) 1.21 vs. CNI monotherapy, 95% CI 1.02-1.43, p = 0.026), in a time-updating as-treated analysis (aHR 1.61, 95% CI 1.34-1.93; p < 0.001) and when measured as cumulative exposure (aHR 1.13 per 6-month increase, 95% CI: 1.02-1.33; p = 0.027). More southern latitude of residence was also independently associated with incident KC with an aHR of 1.26 per 5°N decrease towards the Equator (95% CI: 1.08-1.47, p = 0.003). We demonstrate independent effects of CNI with antiM immunosuppression regimen and latitude of residence on the risk of post-LT KC, which will better inform screening practices and immunosuppression management. (© 2024. The Author(s).) |
| References: | O’Reilly Zwald F, Brown M (2011) Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 65(2):253–261. (PMID: 10.1016/j.jaad.2010.11.06221763561) Euvrard S, Kanitakis J, Claudy A (2003) Skin cancers after organ transplantation. N Engl J Med 348(17):1681–1691. (PMID: 10.1056/NEJMra02213712711744) Jambusaria-Pahlajani A, Crow LD, Lowenstein S et al (2019) Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study. Transpl International: Official J Eur Soc Organ Transplantation 32(12):1259–1267. (PMID: 10.1111/tri.13493) Garrett GL, Blanc PD, Boscardin J et al (2017) Incidence of and risk factors for skin Cancer in Organ Transplant recipients in the United States. JAMA Dermatology 153(3):296–303. (PMID: 10.1001/jamadermatol.2016.492028097368) Kwong AJ, Kim WR, Lake JR et al (2024) OPTN/SRTR 2022 Annual Data Report: liver. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg 24(2s1):S176–s265. (PMID: 10.1016/j.ajt.2024.01.014) Bittermann T, Lewis JD, Goldberg DS (2022) Recipient and Center factors Associated with Immunosuppression Practice beyond the First Year after Liver Transplantation and Impact on outcomes. Transplantation 106(11):2182–2192. (PMID: 10.1097/TP.0000000000004209357061039613480) Lucey MR, Terrault N, Ojo L et al (2013) Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplantation: Official Publication Am Association Study Liver Dis Int Liver Transplantation Soc 19(1):3–26. (PMID: 10.1002/lt.23566) EASL Clinical Practice Guidelines (2016) Liver transplantation. J Hepatol 64(2):433–485. (PMID: 10.1016/j.jhep.2015.10.006) Kim DS, Yoon YI, Kim BK et al (2024) Asian Pacific Association for the study of the liver clinical practice guidelines on liver transplantation. Hepatol Int 18(2):299–383. (PMID: 10.1007/s12072-023-10629-338416312) Crombie IK (1979) Variation of melanoma incidence with latitude in North America and Europe. Br J Cancer 40(5):774–781. (PMID: 10.1038/bjc.1979.2605085802010099) Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN (2002) Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 147(5):950–956. (PMID: 10.1046/j.1365-2133.2002.04976.x12410706) Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN (2003) Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 49(3):397–406. (PMID: 10.1067/S0190-9622(03)00902-212963901) Granata S, Tessari G, Stallone G, Zaza G (2023) Skin cancer in solid organ transplant recipients: still an open problem. Front Med (Lausanne) 10:1189680. (PMID: 10.3389/fmed.2023.118968037153100) Mezochow AK, Schaubel DE, Peyster EG, Lewis JD, Goldberg DS, Bittermann T (2024) Hospitalizations for opportunistic infections following transplantation and associated risk factors: a national cohort study of Medicare beneficiaries. Transpl Infect Disease: Official J Transplantation Soc :e14317. Stepanova M, Al Qahtani S, Mishra A, Younossi I, Venkatesan C, Younossi ZM (2020) Outcomes of liver transplantation by insurance types in the United States. Am J Manag Care 26(4):e121–e126. (PMID: 10.37765/ajmc.2020.4283932270989) Centers for Medicare and Medicaid Services. Prescription drugs (outpatient) (2024) ; https://www.medicare.gov/coverage/prescription-drugs-outpatient . Accessed June 1, 2024. Acuna SA, Huang JW, Scott AL et al (2017) Cancer Screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg 17(1):103–114. (PMID: 10.1111/ajt.13978) Renzi C, Mastroeni S, Mannooranparampil TJ et al (2010) Delay in diagnosis and treatment of squamous cell carcinoma of the skin. Acta dermato-venereologica 90(6):595–601. (PMID: 10.2340/00015555-096621057742) Bittermann T, Lewis JD, Goldberg DS (2022) Recipient and center factors associated with immunosuppression practice beyond the first year after liver transplantation and impact on outcomes. Transplantation ;In press. Bittermann T, Kathawate RG, Schaubel DE, Lewis JD, Goldberg DS (2024) Hospital readmission for acute kidney injury is independently associated with de novo end-stage renal disease after liver transplantation. Liver Transpl. Nashan B (2018) mTOR inhibition and clinical transplantation: liver. Transplantation 102(2S Suppl 1):S19–s26. (PMID: 10.1097/TP.000000000000169028230639) Bittermann T, Hubbard RA, Lewis JD, Goldberg DS (2019) The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg 19(12):3319–3327. (PMID: 10.1111/ajt.15513) Rogers HW, Weinstock MA, Feldman SR, Coldiron BM (2015) Incidence Estimate of Nonmelanoma skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatology 151(10):1081–1086. (PMID: 10.1001/jamadermatol.2015.118725928283) Kalbfleisch JD, Prentice RL (2002) The Statistical Analysis of Failure Time Data. Wiley, New York, NY. (PMID: 10.1002/9781118032985) Gibson JAG, Cordaro A, Dobbs TD et al (2021) The association between immunosuppression and skin cancer in solid organ transplant recipients: a control-matched cohort study of 2,852 patients. Eur J Dermatol 31(6):712–721. (PMID: 10.1684/ejd.2021.410834427560) Vos M, Plasmeijer EI, van Bemmel BC et al (2018) Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation. J Heart Lung Transpl 37(7):853–859. (PMID: 10.1016/j.healun.2018.03.012) Cho HG, Kuo KY, Xiao K et al (2018) Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol 78(1):27–28e21. (PMID: 10.1016/j.jaad.2017.09.06328989107) Zhang J, Miller CJ, O’Malley V, Etzkorn JR, Shin TM, Sobanko JF (2018) Patient quality of life fluctuates before and after Mohs micrographic surgery: a longitudinal assessment of the patient experience. J Am Acad Dermatol 78(6):1060–1067. (PMID: 10.1016/j.jaad.2018.02.06529518455) Sobanko JF, Sarwer DB, Zvargulis Z, Miller CJ (2015) Importance of physical appearance in patients with skin cancer. Dermatol Surgery: Official Publication Am Soc Dermatol Surg [et al] 41(2):183–188. (PMID: 10.1097/DSS.0000000000000253) Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC (2016) Azathioprine and risk of skin Cancer in Organ Transplant recipients: systematic review and Meta-analysis. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg 16(12):3490–3503. (PMID: 10.1111/ajt.13863) Pinho A, Gouveia M, Cardoso JC, Xavier MM, Vieira R, Alves R (2016) Non-melanoma skin cancer in Portuguese kidney transplant recipients - incidence and risk factors. An Bras Dermatol 91(4):455–462. (PMID: 10.1590/abd1806-4841.20164891275797404999103) Karia PS, Azzi JR, Heher EC, Hills VM, Schmults CD (2016) Association of Sirolimus Use with risk for skin Cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of Cancer. JAMA Dermatology 152(5):533–540. (PMID: 10.1001/jamadermatol.2015.554826792250) Olszewska B, Imko-Walczuk B, Dębska-Ślizień A (2023) Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review. Postepy Dermatologii i Alergologii 40(2):187–193. (PMID: 10.5114/ada.2023.1276373731291010258712) Lim WH, Eris J, Kanellis J et al (2014) A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg 14(9):2106–2119. (PMID: 10.1111/ajt.12795) Alter M, Satzger I, Schrem H, Kaltenborn A, Kapp A, Gutzmer R (2014) Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. J Der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatology: JDDG 12(6):480–488. Murray SL, Daly FE, O’Kelly P et al (2020) The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Ren Fail 42(1):607–612. (PMID: 10.1080/0886022X.2020.1785499326054137946013) Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ (2017) The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int 91(4):954–963. (PMID: 10.1016/j.kint.2016.11.00828109543) Rizvi SMH, Aagnes B, Holdaas H et al (2017) Long-term change in the risk of skin Cancer after organ transplantation: a Population-based Nationwide Cohort Study. JAMA Dermatology 153(12):1270–1277. (PMID: 10.1001/jamadermatol.2017.2984290496125817449) Menzies S, O’Leary E, Callaghan G et al (2019) Declining incidence of keratinocyte carcinoma in organ transplant recipients. Br J Dermatol 181(5):983–991. (PMID: 10.1111/bjd.1809431049932) Wisgerhof HC, Wolterbeek R, de Fijter JW, Willemze R, Bouwes Bavinck JN (2012) Kidney transplant recipients with cutaneous squamous cell carcinoma have an increased risk of internal malignancy. J Invest Dermatol 132(9):2176–2183. (PMID: 10.1038/jid.2012.13222534875) Nazzal M, Lentine KL, Naik AS et al (2018) Center-driven and clinically driven variation in US liver transplant maintenance immunosuppression therapy: a national practice patterns analysis. Transplantation Direct 4(7):e364. (PMID: 10.1097/TXD.0000000000000800300466546056277) Axelrod DA, Naik AS, Schnitzler MA et al (2016) National Variation in Use of Immunosuppression for kidney transplantation: a call for evidence-based regimen selection. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg 16(8):2453–2462. (PMID: 10.1111/ajt.13758) Lloyd A, Klintmalm G, Qin H, Menter A (2015) Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations. Clin Transplant 29(2):110–117. (PMID: 10.1111/ctr.1249025530232) Gogia R, Binstock M, Hirose R, Boscardin WJ, Chren MM, Arron ST (2013) Fitzpatrick skin phototype is an independent predictor of squamous cell carcinoma risk after solid organ transplantation. J Am Acad Dermatol 68(4):585–591. (PMID: 10.1016/j.jaad.2012.09.03023107311) |
| معلومات مُعتمدة: | P30-DK050306 United States DK NIDDK NIH HHS; K08-DK117013 United States DK NIDDK NIH HHS; R01-AG079911 United States AG NIA NIH HHS |
| فهرسة مساهمة: | Keywords: Immunosuppression; Keratinocyte carcinoma; Latitude; Liver transplantation |
| المشرفين على المادة: | 0 (Immunosuppressive Agents) 0 (Calcineurin Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240926 Date Completed: 20240926 Latest Revision: 20240926 |
| رمز التحديث: | 20240926 |
| DOI: | 10.1007/s00403-024-03404-3 |
| PMID: | 39325226 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-069X |
|---|---|
| DOI: | 10.1007/s00403-024-03404-3 |